Keyword: Puma Biotechnology
The pivotal trial linked the tyrosine kinase inhibitor to reduced risk of progression and death in patients with and without brain metastases.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
A panel of experts voted 12 to 4 in favor of approving Puma's breast cancer adjuvant therapy neratinib.
Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib.
The U.S. Securities & Exchange Commission has hit Puma Biotechnology’s former senior director of regulatory affairs Robert Gadimian with an insider trading charge.